Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences
PR Newswire
RICHMOND, Calif., Sept. 24, 2018
RICHMOND, Calif., Sept. 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. SGMO announced today that management will participate in the following healthcare investor and industry conferences in September and October.
- 2018 Jefferies Gene Therapy Summit, New York, NY, September 27, 2018
Sangamo's presentation is scheduled for 2:05 p.m. ET on Thursday. - Cantor Fitzgerald 2018 Global Healthcare Conference, New York, NY, October 1-3, 2018
Sangamo's presentation is scheduled for 12:15 p.m. ET on Tuesday, October 2nd. - ARM Cell & Gene Meeting on the Mesa, La Jolla, CA, October 3-5, 2018
Sangamo's presentation is scheduled for 3:15 p.m. PT on Wednesday, October 3rd. Earlier that day, Sandy Macrae, CEO of Sangamo, is also scheduled to participate in a panel discussion titled, "Spotlight: Commercializing Gene Therapies for Hemophilia" at 10:45 a.m. PT. - 2018 Chardan Genetic Medicines Conference, New York, NY, October 9, 2018
Sangamo's presentation is scheduled for 3:15 p.m. ET on Tuesday.
The presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will be archived on the Sangamo website for two weeks after the events.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-participation-at-upcoming-investor-and-industry-conferences-300717740.html
SOURCE Sangamo Therapeutics, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.